Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2016-02-01 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于为全资子公司医药商业有限公司提供500万元担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding providing a 5 million RMB guarantee for its wholly-owned subsidiary. It details the guarantee amount, the subsidiary's financial status, and the board's opinion on the guarantee. The document is a formal announcement about a financing-related guarantee but does not contain financial statements or detailed financial performance data. It is not an annual or interim report, nor an earnings release. It is not a regulatory certification or a voting result. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and guarantees provided.
2016-02-01 Chinese
关于投资广州桔叶信息科技有限公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding its investment in Guangzhou Juye Information Technology Co., Ltd. It details the investment amount, the company's board approval, the investment contract terms, and risk analysis. The document is a formal public announcement about a financing/investment activity, not a financial report or earnings release. It does not contain financial statements or detailed financial performance data. The document length is 3180 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP), as it provides an update on the company's investment and capital allocation activities.
2016-02-01 Chinese
关于修订血塞通注射剂相关事宜的补充说明公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Group Co., Ltd. regarding revisions to the product instructions for their injection product 'Xuesaitong Injection'. It includes extensive data on production, sales, adverse reactions, regulatory requirements from the China Food and Drug Administration (CFDA), and company responses to regulatory changes and market risks. The document is not a full financial report, earnings release, or management discussion, but rather a regulatory and product-related disclosure. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement about product information and compliance with CFDA requirements, including risk disclosures and historical product development information. This type of document aligns best with Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-01-27 Chinese
关于全资公司昆明中药厂有限公司板蓝清热颗粒获批国家中药二级保护品种的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the approval of a product (板蓝清热颗粒) by the national regulatory authority (CFDA) as a protected traditional Chinese medicine variety. It details product information, market potential, and strategic implications. The document is an official company announcement about a regulatory approval and product status, not a financial report, management change, or shareholder meeting material. It does not contain financial statements, earnings data, or voting results. It is a regulatory announcement about product approval and protection status, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2016-01-25 Chinese
2016年第一次临时股东大会的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the convening, attendance, voting procedures, and results of a company's 2016 first extraordinary general meeting (临时股东大会). It discusses the legality and validity of the meeting and resolutions passed. It does not contain financial statements or detailed financial data, nor is it a report or announcement of financial results. It is not a proxy solicitation or voting results announcement but a legal opinion on the meeting's compliance. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal opinion related to a shareholder meeting, not the meeting materials themselves or the voting results announcement.
2016-01-21 Chinese
2016年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of resolutions passed at the 2016 first extraordinary shareholders' meeting of Kunming Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results on specific proposals, and legal witness statements. The content focuses on the voting outcomes and procedural compliance rather than presenting a full report or financial statements. The document length is relatively short (2324 characters) and it serves as an official announcement of voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2016-01-21 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.